Imunon, Inc. Advances Phase 3 Trial for Innovative Cancer Treatment

Imunon, Inc. ((IMNN)) announced an update on their ongoing clinical study.

Imunon, Inc. is conducting a Phase 3 clinical trial titled A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer. The study aims to assess the safety and efficacy of the drug IMNN-001, in combination with standard chemotherapy, for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. This trial is significant as it explores a potentially more effective treatment regimen for these types of cancer.

The intervention being tested is IMNN-001, an IL-12 plasmid formulated with PEG-PEI-Cholesterol Lipopolymer, administered intraperitoneally. It is intended to enhance the efficacy of standard chemotherapy regimens by boosting the immune response.

This interventional study uses a randomized, parallel assignment model without masking, focusing on treatment as its primary purpose. Participants are randomly assigned to receive either the experimental treatment of IMNN-001 with standard chemotherapy or the control treatment of standard chemotherapy alone.

The study is set to start on July 11, 2025, with the primary completion date yet to be determined. The last update was submitted on July 7, 2025. These dates are crucial as they mark the timeline for the trial’s progression and potential availability of results.

The market implications of this study could be significant for Imunon, Inc., as positive results may enhance investor confidence and potentially boost stock performance. In the competitive landscape of cancer treatment, advancements in therapy options can influence market dynamics and investor sentiment.

The study is currently recruiting, and further details are available on the ClinicalTrials portal.